Skip to main content
. 2014 Feb;29(Suppl 1):i54–i62. doi: 10.1093/ndt/gft342

FIGURE 1:

FIGURE 1:

Progress in the study of TWEAK as a therapeutic target in kidney injury. Understanding the role and regulation of TWEAK and Fn14 in kidney injury has progressed very rapidly since the early functional studies published in 2006 to clinical trials in kidney disease launched in 2012. RA, rheumatoid arthritis; LN, lupus nephritis; Ab, antibody.